Use of a COPD care pathway heightened the odds for a pulmonary rehabilitation referral and home discharge in hospitalized ...

COPD is one of the most common lung conditions in the country. If you experience shortness of breath, wheezing or difficulty ...

Brilaroxazine has a novel mechanism of action for treating the underlying disruption in serotonin signaling implicated in the pathogenesis of Pulmonary Fibrosis CUPERTINO, Calif., Nov. 10, 2025 (GLOBE ...

Join Rich Jones and Dr Mitchell Rothstein as they talk advances in COPD treatment. FREE lunch from Carrabba’s Italian Grill ...

Key points A 53-year-old woman with rectosigmoid adenocarcinoma was seen in the radiation oncology clinic for her fifth and final fraction of neoadjuvant radiotherapy, where she reported chills, ...

Patients with type 2 diabetes who use GLP-1 receptor agonists have a significantly lower risk for lung cancer than those who ...

Brensocatib, a DPP1 inhibitor, is the first FDA-approved therapy for non-cystic fibrosis bronchiectasis, showing significant clinical and structural benefits. The ASPEN trial demonstrated that ...

RedChip Companies will air interviews with Connect Biopharma Holdings Limited (Nasdaq:CNTB) and Bimergen Energy Corp.

The findings position SII as a potentially valuable biomarker for risk stratification in patients with COPD and AF, with the identified threshold potentially serving as a clinical decision point for ...

Emerging research highlights the transformative potential of m6A RNA modification in the diagnosis and treatment of ...

The Company reported a net loss of approximately $4.0 million, or $0.06 per share, for the three months ended September 30, ...

The CT-based whole-lung radiomic nomogram accurately identifies AECOPD and offers a robust tool for clinical diagnosis and treatment planning.